Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05042206
Recruitment Status : Recruiting
First Posted : September 13, 2021
Last Update Posted : October 21, 2021
Sponsor:
Information provided by (Responsible Party):
Pharmicell Co., Ltd.

Brief Summary:

This clinical trial is an open, single-center, phase 1 clinical trial to evaluate the safety of allogeneic bone marrow-derived mesenchymal stem cell injection in patients with chronic kidney disease.

The purpose is to evaluate the safety for 12 months after administration of Cellgram-CKD 3 times in 10 patients with chronic kidney disease.


Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Stage 3B Chronic Kidney Disease stage4 Biological: Cellgram-CKD Phase 1

Detailed Description:

The screening test is performed after the clinical trial subject consents in writing to participate in the clinical trial.

Subjects who meet the inclusion/exclusion criteria are registered in the clinical trial, and Cellgram-CKD is injected intravenously by puncturing a vein with a needle. After injecting Cellgram-CKD three times at an interval of 2 weeks (14 days), the subject visits the testing institution at 1 month, 3 months, 6 months, 9 months and 12 months for safety evaluation.

However, since the safety of Cellgram-CKD has not been established, proceed as follows.

In the first 3 subjects who received the investigational product, if no adverse events of Grade 3 or higher according to the NCI-CTCAE related to the investigational product occur 14 days after the 1st and 2nd administration, and 1 month after the 3rd administration, the remaining subjects were sequentially treated. Register as a member and conduct clinical trials.

If an adverse event of Grade 3 or higher according to the NCI-CTCAE standard related to the test drug occurs in two of the first three subjects, the clinical trial is terminated early. is conducted by registering three additional test subjects in the same way as the first.

If one or more of the three subjects develops a Grade 3 or higher adverse event related to the investigational product, the clinical trial is terminated early, and the remaining subjects are treated only if all three subjects do not have a Grade 3 or higher adverse reaction related to the investigational product. Register to continue the clinical trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Patients With Chronic Kidney Disease
Estimated Study Start Date : October 2021
Estimated Primary Completion Date : April 2023
Estimated Study Completion Date : April 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: Cellgram-CKD

Subjects receive a safety evaluation at 1 month, 3 months, 6 months, 9 months and 12 months after intravenous infusion of Cellgram-CKD 10mL at intervals of 2 weeks (14 days) 3 times.

In the case of Cellgram-CKD, a milky white cell suspension solution is filled in a colorless and transparent plastic syringe, and the syringe tip is fixed with an obturator.

Biological: Cellgram-CKD
Allogeneic bone marrow-derived mesenchymal stem cell therapy for the treatment of chronic kidney disease




Primary Outcome Measures :
  1. Incidence of adverse event, and the level of the adverse event (AE) analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0) [ Time Frame: Adverse events are collected from the first administration of the investigational product to 12 months after the third administration of the investigational product. ]
    The primary endpoint is an adverse event, and the level of the adverse event (AE) is analyzed according to the Common Terminology Criteria for Adverse Event (CTCAE) (version 5.0).


Secondary Outcome Measures :
  1. Changes in eGFR [ Time Frame: 1, 3, 6, 9, and 12 months of administration of the investigational product ]
    Changes in eGFR after 1, 3, 6, 9, and 12 months of administration of the investigational product compared to the baseline

  2. Changes in BUN [ Time Frame: 1, 3, 6, 9, and 12 months of administration of the investigational product ]
    Changes in BUN after 1, 3, 6, 9, and 12 months of administration of the investigational product compared to the baseline

  3. Changes in Creatinine [ Time Frame: 1, 3, 6, 9, and 12 months of administration of the investigational product ]
    Changes in Creatinine after 1, 3, 6, 9, and 12 months of administration of the investigational product compared to the baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female between the ages of 19 and 79
  • Those diagnosed with CKD stage 3b or 4 [eGFR 15 - 44 ml/min/1.73 m2] within 1 year before screening
  • Those who voluntarily participated in the clinical trial and signed the Informed consent form

Exclusion Criteria:

  • Those with severe cardiovascular disease (angina, myocardial infarction, unstable arrhythmia, heart failure, etc.) at the screening visit
  • Those with the following medical history/comorbidities A. Gentamicin hypersensitivity reaction B. Solid cancer or malignant blood disease within 5 years prior to screening C. Clinically significant cognitive disorder, dementia or psychiatric disorder D. Alcohol or drug abuse E. Severe respiratory disease (COPD, asthma, pneumonia, pulmonary embolism, pneumothorax, etc.) F. Stroke G. Systemic autoimmune disease
  • Those whose test results fall under the following at the screening visit A. Pathogenic microorganism test (Hbs Ag, HCV Ab, HIV Ab, Syphilis) positive B. Uncontrolled hypertension (systolic blood pressure >190 mmHg or diastolic blood pressure >100 mmHg) or hypotension (systolic blood pressure <90 mmHg or diastolic blood pressure <50 mmHg) C. AST and ALT ≥ upper limit of normal x 3.0 D. Total bilirubin ≥ upper limit of normal x 1.5
  • At screening, those who have the following treatment history A. Those who are being treated for severe systemic infection B. Those who have been treated with immunosuppressant within 28 days prior to screening
  • Those with a history of renal transplantation
  • Those who have received dialysis within 3 months prior to the screening visit or who are planning to undergo dialysis during the clinical trial period
  • Pregnant, lactating, or planning during clinical trials
  • Those who do not agree to comply with the contraceptive method specified in this protocol during the clinical trial period
  • Those who are receiving drugs that are expected to affect the results of this clinical trial when judged by the investigator
  • Those who participated in other interventional clinical trials within 4 weeks prior to the screening visit and received investigational products/medical devices for investigational use or received procedures
  • Those who have or are planning to administer other cell therapy products
  • Those who are judged by the investigator to be inappropriate to participate in this clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05042206


Contacts
Layout table for location contacts
Contact: Jho Hyunwoo +82, 2-3496-0135 hwjho92@pharmicell.com

Locations
Layout table for location information
Korea, Republic of
Asan Medical Center Recruiting
Seoul, Korea, Republic of
Contact: Hyosang Kim, associate professor    +82, 2-3010-1439    mateus@amc.seoul.kr   
Sponsors and Collaborators
Pharmicell Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Kim Hyosang Asan Medical Center Nephrology
Layout table for additonal information
Responsible Party: Pharmicell Co., Ltd.
ClinicalTrials.gov Identifier: NCT05042206    
Other Study ID Numbers: PMC-P-12
First Posted: September 13, 2021    Key Record Dates
Last Update Posted: October 21, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency